The ESG Investment Case in Healthcare: Separating Signal from Noise

ESG in healthcare has arrived at an inflection point that forces a distinction between two different things: the political debate about whether ESG frameworks should exist, and the empirical evidence about whether they affect financial outcomes. The political debate is loud. The empirical evidence is clear. MSCI’s research documents a significant historical correlation between a company’s ESG rating and its financing costs in both equity and debt markets. Sustainalytics, S&P, and Moody’s reach similar conclusions through different methodologies. For institutional capital allocators — pension funds, sovereign wealth funds, university endowments — ESG scores are embedded in screening processes that determine capital flows. Healthcare companies that dismiss this as a passing trend are making a bet against the direction of money.

How ESG Ratings Work in Healthcare — and Why They Matter

MSCI’s ESG rating methodology, which covers more than 10,000 companies and produces ratings from CCC to AAA, assesses 35 distinct ESG issues with weights calibrated to their financial materiality for each specific industry. For healthcare and pharmaceutical companies, the key material issues differ from those in energy or finance. Product safety and quality — the risk of drug recalls, adverse event reporting failures, and regulatory violations — is weighted heavily. Access to healthcare (including pricing strategy, geographic reach, and affordability programmes) carries significant weight. Clinical trial data integrity, supply chain labour practices, and environmental management complete the primary issue set. Board governance and executive compensation structure are assessed across all industries.

The MSCI 2026 ESG Ratings model update, released in October 2025, introduced supply chain forced labour exposure as an increased risk focus — reflecting the EU Forced Labour Regulation, the US Uyghur Forced Labor Prevention Act, and the Modern Slavery Acts across the UK, Australia, and Canada. For pharmaceutical companies with complex API manufacturing supply chains concentrated in specific geographies, this adjustment affects how MSCI scores supply chain governance. Companies that have invested in supplier auditing, disclosed their manufacturing sub-supplier relationships, and demonstrated corrective action capability will score better on this factor than those whose disclosure remains at the tier-one level.

MSCI’s research into healthcare funds and UN Sustainable Development Goal 3 (Good Health and Well-Being) found that only 47 funds investing globally in healthcare had greater than 50% alignment with SDG 3, comprising just 0.51% of all healthcare funds but 15% of total healthcare fund assets. The most-favoured companies among SDG3-aligned funds were US biotech companies — a data point that reflects the dual nature of biotech’s ESG position: high on social impact (developing medicines for unmet needs) but often lower on environmental and governance infrastructure than large pharmaceutical peers.

The Sector’s Sustainability Leaders

Across multiple independent frameworks, a consistent group of companies leads on ESG performance in pharmaceutical and healthcare:

• Novartis topped the 2024 Access to Medicine Index for the first time, ranked 11th in Time’s World’s Most Sustainable Companies 2025, and holds carbon neutrality commitments across Scopes 1, 2, and 3 by 2040. Its tiered pricing strategy, inclusive business model covering 102 LMICs, and MSCI ESG rating place it among the sector’s most comprehensively positioned companies. Its carbon-neutral manufacturing programme has also generated 28% operating cost savings.
• AstraZeneca holds the sector’s most ambitious supplier target (95% with science-based emissions targets by 2025), ranked 19th in Time’s Most Sustainable 2025, and leads the sector’s transition to green chemistry in R&D. Its inhaler reformulation programme — replacing greenhouse gas propellants — addresses a significant Scope 3 emissions source with no clinical compromise.
• GSK ranked second in the 2024 Access to Medicine Index with the largest priority pipeline and broadest geographic coverage among comparators. Its net-zero Scope 1 and 2 targets are set for 2030, with a whole-value-chain net-zero target for the biopharma business.
• Sanofi ranked third in the 2024 Access to Medicine Index, tenth in Time’s Most Sustainable 2025, and co-launched the Activate initiative at COP27 alongside AstraZeneca, Bristol Myers Squibb, GSK, Johnson & Johnson, and Pfizer to collectively decarbonise pharmaceutical supply chains.
• Roche has committed to net zero across all emission scopes by 2045, introduced trial-level carbon accounting for all Phase 2 and 3 studies starting in 2025, and updated joint supplier sustainability targets with six peer companies in November 2025. Its Elecsys diagnostics division also benefits commercially from the blood-based biomarker expansion that is reshaping neurological diagnosis.

Reading ESG Risk in Biotech Investment

For investors evaluating individual biotech companies, ESG risk has a different shape than it does for large pharmaceutical incumbents. Early-stage biotechs typically lack the governance infrastructure, supplier auditing capacity, and sustainability reporting apparatus of mature companies. MSCI applies methodological adjustments for companies with limited data — assigning industry averages for issues where company-specific data is unavailable, which generally disadvantages smaller companies relative to larger peers with more developed disclosure programmes. Investors using ESG screens to evaluate biotech should understand that a lower MSCI score at a clinical-stage biotech may reflect disclosure immaturity rather than genuine ESG risk.

The areas of genuine ESG risk most relevant to biotech investment are the following:

• Clinical trial data integrity: Biotech’s asset value rests almost entirely on clinical data. Governance of data collection, statistical analysis, and regulatory submission is an ESG governance risk that is directly financially material. Companies with robust data management practices, independent data safety monitoring boards, and clean regulatory histories carry lower risk profiles.
• IP and access commitments: Biotechs that develop medicines for rare diseases or conditions with high global disease burden face growing investor and regulatory pressure to articulate access commitments before approval — including pricing strategy, tiered access plans, and voluntary licensing intentions. Investors who hold positions through approval should factor in the reputational and regulatory risk of access controversies.
• Supply chain concentration: API manufacturing concentrated in single geographies creates both MSCI forced-labour exposure risk and supply chain resilience risk. This has been amplified by tariff volatility and geopolitical tension affecting pharmaceutical manufacturing in Asia.
• Workforce governance: In pre-revenue biotechs, human capital is both the primary asset and the primary ESG risk. High executive turnover, equity compensation controversies, and pay equity gaps all affect the MSCI governance score — and have direct operational consequences in an industry where key personnel risk is existential.

The Anti-ESG Environment and Its Financial Implications

Executive Order 14366 and the broader US deregulatory environment in 2026 have not reversed the financial materiality of ESG performance in healthcare — but they have changed its communication and enforcement landscape. US healthcare companies are reducing the prominence of ESG language in domestic investor communications while maintaining the underlying programmes required for European regulatory compliance and institutional investor access. The bifurcation is real: the same company may produce a detailed CSRD-compliant sustainability report for European regulators and a stripped-back, financially-framed ESG disclosure for US audiences.

For investors, this communication bifurcation creates an information quality problem. The signal to look for is not the prominence of ESG language in investor communications — that has become unreliable as a quality indicator — but the specificity of disclosed metrics: trial-level carbon figures, supplier audit results, access programme patient-reach data, board composition data, and executive incentive structures linked to sustainability targets. Companies that disclose at that level of specificity are, regardless of their political positioning, building the infrastructure for durable ESG performance. Those that have reduced disclosure while announcing broad commitments have reversed the precedence.

Author

Bernice Lottering